



Food and Drug Administration Advisory Committee Member Acknowledgment of Financial Interests

Name of Advisory Committee Member: Jeffrey R. Strawn, M.D., F.A.A.C.A.P.

Committee: Pediatric Advisory Committee

Meeting Date: September 15, 2020

I acknowledge that contingent upon public disclosure of the following financial interest(s) related to the agenda item: discussion regarding acute hyperkinetic movement disorder associated with the combined use of ADHD stimulants and antipsychotics (including first-generation antipsychotics and second-generation antipsychotics), I may be considered for participation in the advisory committee meeting described above.

Type of Interest	Nature	Magnitude
I Personal/Immediate Family		
Describe type of interest; e.g.: Stocks/investments; Employment; Work as consultant/advisor; Contracts/grants; Patents/royalties/trademarks; Work as an expert witness; Teaching/speaking/writing]	[Describe nature of interest; e.g.: sponsor, competitor, affected firm]	[Describe magnitude of interest; e.g.: \$ 0 - 5,000; \$ 5001 - 10,000; \$ 10,001 - 25,000; \$ 25,001 - 50,000)
II Other Imputed Interests		
Employment: contracts/grants	Product that will be used as an example in FDA public presentation	(b) (4)

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

8/26/2020

Signature

Date

/s/